CTLA4 and hypophysitis: One study reported that among 273 patients with malignant melanoma and prostate cancer treated with ipilimumab, a monoclonal antibody directed against cytotoxic T-lymphocyte antigen-4 (CTLA-4), 9 (3.3%) were diagnosed with hypophysitis.